Anti-Angiogenesis Effects Induced by Octaminomycins A and B against HUVECs |
Jang, Jun-Pil
(Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology)
Han, Jang Mi (Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University) Jung, Hye Jin (Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University) Osada, Hiroyuki (Chemical Biology Research Group, RIKEN Center for Sustainable Research Science) Jang, Jae-Hyuk (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology) Ahn, Jong Seog (Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology) |
1 | Staton CA, Reed MW, Brown NJ. 2009. Acritical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90: 195-221. DOI |
2 | Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. 2004. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56: 549-580. DOI |
3 | Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell. Biol. 7: 359-371. DOI |
4 | Hass TL. 2005. Endothelial cell regulation of matrix metalloproteinases. Can. J. Physiol. Pharmacol. 83: 1-7. DOI |
5 | Ne wman DJ, Cragg GM. 2016. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79: 629-661. DOI |
6 | Cragg GM, Newman DJ. 2013. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 1830: 3670-3695. DOI |
7 | Clardy J, Fischbach MA, Walsh CT. 2006. New antibiotics from bacterial natural products. Nat. Biotechnol. 24: 1541-1550. DOI |
8 | Genilloud O, Gonzalez I, Salazar O, Martin J, Tormo JR, Vicente F. 2011. Current approaches to exploit actinomycetes as a source of novel natural products. J. Ind. Microbiol. Biotechnol. 38: 375-359. DOI |
9 | Nett M, Ikeda H, Moore BS. 2009. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat. Prod. Rep. 26: 1362-1384. DOI |
10 | Kerbel R, Folkman J. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739. DOI |
11 | Jubb AM, Oates AJ, Holden S, Koeppen H. 2006. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer 6: 626-635. DOI |
12 | Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69: 4-10. DOI |
13 | Jang JP, Nogawa T, Futamura Y, Shimizu T, Hashizume D, Takahashi S, et al. 2017. Octaminomycins A and B, cyclic octadepsipeptides active against Plasmodium falciparum. J. Nat. Prod. 27: 134. |
14 | Ferrara N. 2004. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9: 2-10. DOI |
15 | Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18: 4-25. DOI |
16 | Berqurs G, Hanahan D. 2008. Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer 8: 592-603. DOI |